Multicenter phase II study of modified FOLFOX6 and bevacizumab in chemonaive advanced or recurrent colorectal cancer.
Phase 2
- Conditions
- Colorectal Cancer
- Registration Number
- JPRN-UMIN000001490
- Lead Sponsor
- Yakult Honsha Co.,Ltd.
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 65
Inclusion Criteria
Not provided
Exclusion Criteria
Patient with contraindication to oxaliplatin, 5-FU, l-LV, or Bevacizumab.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method